Navigation Links
Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Date:11/3/2008

use it is minimally excreted in the kidneys, betrixaban may be the only drug of its kind available for the large and growing population of moderately and severely renally-impaired patients who are at high risk for bleeding. This would dramatically expand the treatment index for this type of drug."

Betrixaban has been specifically designed to have ideal properties for chronic therapy and to be the only true, once-daily oral anticoagulant with distinct advantages over other currently available anticoagulants or those in clinical trials such as rivaroxaban, apixaban and dabigatran.

Betrixaban inhibits Factor Xa, a validated target for which there are approved drugs on the market. Inhibiting Factor Xa activity appears to offer advantages over other anticoagulation targets. Portola believes betrixaban will offer several key differentiating features including a long half-life and a low peak-to-trough drug concentration ratio to support once-daily dosing and the potential for an improved benefit/risk profile. Betrixaban is minimally excreted through the kidneys and therefore, unlike other novel agents, may not require dose adjustment in patients with moderately impaired renal function and may be the only novel oral anticoagulant available for patients with severe renal disease. And because betrixaban is neither an inhibitor nor an inducer of cytochrome P450 enzymes, it minimizes the risk of drug-drug interactions often seen with other Factor Xa inhibitors in development and with warfarin.

Portola has completed EXPERT, a 200-patient Phase II trial, demonstrating betrixaban's clinical proof of concept in preventing venous thromboembolism in patients undergoing knee replacement surgery. Preclinical and Phase I studies, in addition to EXPERT, have shown that betrixaban is well tolerated over a range of dose levels.

Portola may develop betrixaban for additional indications including prevention of venous thromboembolism (VTE) in medically ill patients
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 With ... increase of personal health expenditure as well as ... care system, China diagnostic reagent industry has been ... over 90%. In 2013, Chinese in vitro diagnostics ... billion came from in vitro diagnostic reagents. ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 BCC ... Global Markets for Enzymes in Industrial Applications , ... reach to nearly $7.1 billion by 2018, registering a ... growth is estimated to be recorded in the detergent ... forecast period. , Enzyme technology has influenced almost every ...
(Date:7/30/2014)... July 30, 2014 Yuma Regional ... and complementary therapies brings comprehensive cancer care to ... Yuma Regional Cancer Center has officially opened. A ... program includes services such as open, semi-private and ... American Cancer Society Resource Center, hematology, rehabilitation center, ...
(Date:7/30/2014)... Fla. , July 30, 2014  Dyadic ... biotechnology company whose patented and proprietary technologies are ... and other proteins for the bioenergy, bio-based chemical, ... appointment of Thomas "Tom" Dubinski as Vice President ... for leading the financial and information technology operations ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4
... the American Academy ... of Dermatology, FREEPORT, N.Y., ... and its natural receptor,OCTN- 1, are a natural part of the skin,s ... in photoaged,skin. The data was presented at the Poster Session at the ...
... Feb. 11 Emisphere,Technologies, Inc. (Nasdaq: EMIS ), ... delivery of therapeutic molecules using its,eligen(R) technology, today announced ... CEO & Investor Conference on February 12, 2008 on,its ... page of the,Emisphere Web site at http://www.emisphere.com/ir.asp ...
... On Monday, January 28, The Royal,Marsden Hospital ... Modulated Arc Therapy (VMAT)* treatment in the ... the treatment, the hospital,used its existing Elekta ... control system., (Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO ...
Cached Biology Technology:AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skin's Natural Antioxidant System 2Emisphere Technologies to Web Cast BIO CEO & Investor Conference Presentation February 12 2Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital 2
(Date:7/30/2014)... 2014 ResearchMoz presents this ... Systems Market 2014-2024   Business Strategies, Industry Trends, and ... Market 2014-2024" offers the reader detailed analysis of ... ten years, alongside potential market opportunities to enter ... To view the table of contents for ...
(Date:7/30/2014)... better decisions about what they eat, the Food and ... to the Nutrition Facts label found on nearly every ... Chemical & Engineering News (C&EN), the weekly news ... updates and the fight that has ensued. , ... that while the Nutrition Facts label has remained largely ...
(Date:7/30/2014)... Wallerian degeneration is a subject of major interest ... differentially regulated during the distinct stages of Wallerian ... differentiation and dedifferentiation. Although gene expression responses in ... peripheral nerve injury are known, differences in gene ... unclear. Dr. Dengbing Yao and co-workers from Nantong ...
Breaking Biology News(10 mins):Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10
... Molecular Biology, today publishes its Honey Bee Genome Special ... long-awaited Honey Bee Genome Sequence, published earlier this week ... Sequencing Project (HBGSP), a large scale communal project led ... National Human Genome Research Institute, is expected to usher ...
... Cancer Center at Thomas Jefferson University in Philadelphia and at ... found evidence suggesting that a mutation in a gene that ... a role in the initiation of a major form of ... Michael P. Lisanti, M.D., Ph.D., professor of cancer biology at ...
... of a cell is all about growing and dividing at ... one of the most tightly regulated cellular processes. A control ... cell cycle machinery are produced, activated and degraded to make ... work differently and are usually studied separately, but researchers at ...
Cached Biology News:Looking to a new era in bee research 2Jefferson scientists identify gene mutation potentially involved in breast cancer initiation 2Jefferson scientists identify gene mutation potentially involved in breast cancer initiation 3How nature tinkers with the cellular clock 2
... AMPure is a magnetic bead-based ... no sample transfer, centrifugation or ... small and large PCR extension ... microplates. Agencourt AMPure can easily ...
... efficient enrichment of functional endoplasmic reticulum ... culture. The isolated ER are useful ... pathway analysis. Metabolic abnornalities of ER ... cystic fibrosis and many more ER ...
Blasticidin resistance gene (bsr), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... stabilizing 400g of purified RNA samples., , ... stabilization of aqueous RNA samples that have ... guanidine, phenol/chloroform, silica, oligo dT etc or ... all the necessary components for the stabilization ...
Biology Products: